Chronic graft-versus-host disease (cGVHD) is a major complication of allogeneic hematopoietic cell transplantation (HCT) that occurs in 25-75% of patients, depending on the source of the graft. 1 The typical skin lesions are either lichenoid or sclerodermatous. Patients may also have areas of leucoderma, alopecia, bullae and photosensitivity. [2] [3] [4] While partial leucoderma (hypopigmentation) occurs frequently, total body leucoderma is extremely unusual in cGVHD. One case report in the literature describes a 14-year-old boy in whom total leucoderma of the skin occurred gradually over a few months. This patient had an elevated level of anti-melanocyte antibodies in his serum, which may be responsible for the leucoderma. 5 We describe a patient who developed total leucoderma arising from his cGVHD. In contrast to the previously described case, our patient developed total leucoderma very acutely, over the course of 2 weeks.
A 14-year-old white male underwent a matched-unrelated donor bone marrow transplant in 1987 for chronic myelogenous leukemia. His preparative regimen consisted of busulfan, cytosine arabinoside (Ara-C) and total body irradiation (TBI). The donor marrow was T cell-depleted and he received cyclosporine and steroids as GVHD prophylaxis. He had no significant acute GVHD. However, upon tapering his prophylaxis he experienced chronic GVHD. He had multiple episodes of worsening of his chronic GVHD on tapering of his immunosuppressive medications. These episodes included widespread erythema with lichenoid features, scaling and alopecia. A skin biopsy 5 months after transplant showed acanthosis, exocytosis of mononuclear cells, and a perivascular mononuclear cell infiltrate. The patient responded promptly to higher doses of steroids. After the third attempt to wean his steroid therapy the patient experienced a complete loss of pigment. This phenomenon was first noted when his hair grew in white and was followed by a splotchy depigmentation of the skin. Within 2 weeks he was completely depigmented. There was no other organ system involved. The patient remained on cyclosporine and steroids for more than a year before he tolerated a steroid withdrawal.
Other etiologies of his leucoderma were sought. One year after discontinuing all immunosuppressive therapy he developed transient hypothyroidism. He was originally treated with thyroid replacement, which has since been discontinued, and the patient has remained euthyroid. Of note, there is no family history of autoimmune diseases, hypothyroidism, or vitiligo in the family.
The patient is now 15 years status post his bone marrow transplant and has remained without skin and hair pigmentation. Figure 1 shows a recent photograph. A recent biopsy of his skin was taken from the left lower abdomen to evaluate for the presence of melanin in the epidermis. On routine hematoxylin and eosin staining, melanin granules were not Bone Marrow Transplantation identified in the basilar keratinocytes, nor were any granules seen with Fontana-Masson staining for melanin. Hair follicle epithelium was not seen to evaluate for the presence of bulbar melanin. His skin is very dry but the dryness is controlled with lubricants/moisturizers.
Hypopigmentation is not uncommon in chronic GVHD; however, it is usually patchy and does not involve the majority of the skin. One case of patchy vitiligo has been described in the setting of GVHD although in that case, the authors hypothesize that it may have occurred after treatment of the patient with ganciclovir in the presence of donor T cells expressing herpes simplex virus thymidine kinase. 6 One previous case of total leucoderma (depigmentation) has been described, to our knowledge, in the medical literature. 5 However, our case is significantly different in that it occurred over the course of 2 weeks as opposed to a few months. Nagler et al 5 hypothesized that total leucoderma occurs as an immune response selectively against melanocytes in the skin and hair, as in vitiligo. Furthermore, there is evidence in the literature of T cellmediated vitiligo in a patient who developed melanocyte destruction after antigen-specific immunotherapy of melanoma. 7 The same mechanism could be accounting for the depigmentation during GVHD.
We speculate that the leucoderma in our case may have occurred more acutely since our patient underwent a more intensive preparative regimen (busulfan/Ara-C/TBI) than the previously described patient (cyclophosphamide/total lymph node irradiation). It is conceivable that the very intensive pretransplant regimen rendered the melanocytes exquisitely susceptible to the immune-mediated damage of chronic GVHD. Furthermore, while the association between hypothyroidism and vitiligo is occasionally seen, they are probably not related in his case as the vitiligo preceded the hypothyroidism. The hyopthyroidism is more likely to be secondary to his preparative regimen.
As the histologic findings of his skin biopsy are similar to those seen in vitiligo, one could consider implementing Bone Marrow Transplantation therapy as for that depigmenting cutaneous disorder, although our particular patient is content without treatment. Due to the generalized nature of his depigmentation, therapy with narrow band UVB or photochemotherapy (PUVA) may be useful. Recently, topical tacrolimus has been shown to be effective in patients with localized vitiligo. Transplantation and melanocyte grafting are other potential therapies. 8 Finally, these types of patients require very close followup for cutaneous malignancies, both melanoma and nonmelanoma. Sunscreen, protective clothing and sun avoidance are imperative. While this specific type of patient is very rare, it would seem reasonable that at least annual skin checks (as recommended for vitiligo patients) are a good idea.
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